PAVM logo

PAVMED INC

PAVMNASDAQ
πŸ† #4794 by market capEarnings Mar 29 Β· PostUS Equity
$1.14β–Ό $0.07 (βˆ’5.42%)
Market closed Β· at close
πŸ””
Track PAVM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.4%
7dβ–Ό 25.8%
14dβ–Ό 39.1%
30dβ–Ό 52.5%
ytdβ–Ό 82.5%
1yβ–Ό 88.6%
🏦Market Cap
$9M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-97.6%
Declining
πŸ“ŠGross Margin
-237.8%
Thin
πŸ’΅FCF Margin
-2995.3%
Thin
βš–οΈP/S Ratio
61.3x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.12 – $1.30
52-Week Range
$1.10 – $28.44
Volume (shares)
25,098
Avg Volume (shares)
β€”
Shares Outstanding
8.0M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$71,000
Last Q Revenue
$33,000
P/E Ratio
-0.1
P/S Ratio
61.3x
EPS (TTM)
$-2.97
Dividend Yield
0.00%
Dilution (1yr)
+107.2%
PAVM logo

PAVMED INC

PAVM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$71Kβ–Ό βˆ’97.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-354.9%β–² +249.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$22Mβ–Ό βˆ’51.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5.2Bβ–² +15389.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
774Kβ–² +107.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$12Mβ–² +$19M YoY
StockOtter Β· stockotter.space

About PAVMED INC

PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.